CN115916205A - 使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法 - Google Patents

使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法 Download PDF

Info

Publication number
CN115916205A
CN115916205A CN202180035499.8A CN202180035499A CN115916205A CN 115916205 A CN115916205 A CN 115916205A CN 202180035499 A CN202180035499 A CN 202180035499A CN 115916205 A CN115916205 A CN 115916205A
Authority
CN
China
Prior art keywords
subject
pharmaceutically acceptable
acceptable salt
compound
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035499.8A
Other languages
English (en)
Chinese (zh)
Inventor
H·加伦
E·H·邓
A·维科兹
H-C·范布丁根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of CN115916205A publication Critical patent/CN115916205A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180035499.8A 2020-04-03 2021-04-01 使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法 Pending CN115916205A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063005095P 2020-04-03 2020-04-03
US63/005,095 2020-04-03
US202063051767P 2020-07-14 2020-07-14
US63/051,767 2020-07-14
PCT/US2021/025301 WO2021202825A1 (en) 2020-04-03 2021-04-01 Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
CN115916205A true CN115916205A (zh) 2023-04-04

Family

ID=75625678

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035499.8A Pending CN115916205A (zh) 2020-04-03 2021-04-01 使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法

Country Status (13)

Country Link
US (1) US12605376B2 (https=)
EP (1) EP4125906A1 (https=)
JP (1) JP2023520469A (https=)
KR (1) KR20220163986A (https=)
CN (1) CN115916205A (https=)
AU (1) AU2021249129A1 (https=)
BR (1) BR112022019846A2 (https=)
CA (1) CA3177390A1 (https=)
CL (1) CL2022002699A1 (https=)
IL (1) IL296990A (https=)
MX (1) MX2022012310A (https=)
TW (1) TWI907406B (https=)
WO (1) WO2021202825A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021173740A1 (en) * 2020-02-28 2021-09-02 Genentech, Inc. Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2022240920A1 (en) 2021-05-14 2022-11-17 Loxo Oncology, Inc. Cocrystalline forms of a bruton's tyrosine kinase inhibitor
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途
TW202508592A (zh) * 2023-05-16 2025-03-01 美商建南德克公司 使用布魯頓酪胺酸激酶之抑制劑來治療復發型多發性硬化症之方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
KR20170033358A (ko) 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
WO2017148837A1 (en) 2016-02-29 2017-09-08 F. Hoffmann-La Roche Ag Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
CN107043366B (zh) 2017-04-25 2020-05-26 中国药科大学 4-氨基嘧啶类化合物、其制备方法及医药用途
KR102635949B1 (ko) 2017-05-18 2024-02-14 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 종양 치료용 약물의 제조에 있어서의 ezh2 억제제 및 btk 억제제의 조합물의 용도
WO2019208805A1 (ja) * 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
EP3849559A4 (en) * 2018-09-12 2022-06-01 Denovo Biopharma LLC COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF
TW202042815A (zh) 2019-01-22 2020-12-01 美商建南德克公司 使用布魯頓（bruton）酪胺酸激酶抑制劑治療類風性關節炎、慢性自發性蕁麻疹及全身性紅斑性狼瘡的方法
WO2021173740A1 (en) 2020-02-28 2021-09-02 Genentech, Inc. Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase

Also Published As

Publication number Publication date
EP4125906A1 (en) 2023-02-08
TW202203925A (zh) 2022-02-01
CA3177390A1 (en) 2021-10-07
US20230149395A1 (en) 2023-05-18
BR112022019846A2 (pt) 2022-11-22
AU2021249129A1 (en) 2022-10-20
WO2021202825A1 (en) 2021-10-07
CL2022002699A1 (es) 2023-03-31
JP2023520469A (ja) 2023-05-17
IL296990A (en) 2022-12-01
TWI907406B (zh) 2025-12-11
MX2022012310A (es) 2022-10-27
US12605376B2 (en) 2026-04-21
KR20220163986A (ko) 2022-12-12

Similar Documents

Publication Publication Date Title
CN115916205A (zh) 使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法
JP5819328B2 (ja) ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療
JP2022058443A (ja) 全身性エリテマトーデスの治療のための３－（４－（（４－（モルホリノメチル－ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン
US20240287176A1 (en) Methods of treatment of autoimmune disorders using ilt7 binding proteins
JP2024542148A (ja) ヒト化抗ｃｄ４０抗体の医薬組成物およびその使用
WO2024223740A1 (en) Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha
CN112437665A (zh) 用于治疗及预防多发性硬化症的方法中的经取代氨基-嘧啶化合物
TWI899163B (zh) 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
WO2025045766A1 (en) Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same
RU2858695C2 (ru) Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
TW202517276A (zh) 用於治療自體免疫及發炎疾病之rip1激酶抑制劑之調配物及劑量療法
RU2858696C2 (ru) Способы лечения первично-прогрессирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
HK40087403A (zh) 使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法
HK40082153A (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase
AU2023393624A1 (en) Anti-ilt7 binding agents for the treatment and prevention of myositis
KR20250162587A (ko) 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드
CN117940161A (zh) 伊奈利珠单抗及其在治疗或预防IgG4相关疾病中的使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40087403

Country of ref document: HK